Market Assessment
CymaBay Therapeutics (CBAY) is a small-cap ($873M) clinical-stage biopharma developing innovative therapeutics for rare/orphan diseases and diseases with high unmet medical needs. Seladelpar is a new generation PPAR agonist with excellent safety profile that is devoid of serious adverse events seen with first generation PPAR agonists.
Seladelpar, the lead investigative drug candidate, is in clinical trials for Primary Biliary Cirrhosis and NASH. Recently, seladelpar was granted breakthrough designation for PBC based on the clinical benefits exhibited by seladelpar in the 52-week Phase 2b data readout. CymaBay has multiple shots on